Vildagliptin

Vildagliptin is an oral antihyperglycemic agent belonging to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, a first-line therapeutic option for the management of type 2 diabetes mellitus (T2DM). It is approved for use in adults, either as monotherapy (when diet and exercise alone fail to control blood glucose) or in combination with other antidiabetic drugs (e.g., metformin, sulfonylureas, thiazolidinediones) to improve glycemic control.